319 related articles for article (PubMed ID: 31706993)
1. Cannabidiol increases the nociceptive threshold in a preclinical model of Parkinson's disease.
Crivelaro do Nascimento G; Ferrari DP; Guimaraes FS; Del Bel EA; Bortolanza M; Ferreira-Junior NC
Neuropharmacology; 2020 Feb; 163():107808. PubMed ID: 31706993
[TBL] [Abstract][Full Text] [Related]
2. A pro-nociceptive phenotype unmasked in mice lacking fatty-acid amide hydrolase.
Carey LM; Slivicki RA; Leishman E; Cornett B; Mackie K; Bradshaw H; Hohmann AG
Mol Pain; 2016; 12():. PubMed ID: 27178246
[TBL] [Abstract][Full Text] [Related]
3. Brain-Permeant and -Impermeant Inhibitors of Fatty Acid Amide Hydrolase Synergize with the Opioid Analgesic Morphine to Suppress Chemotherapy-Induced Neuropathic Nociception Without Enhancing Effects of Morphine on Gastrointestinal Transit.
Slivicki RA; Saberi SA; Iyer V; Vemuri VK; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2018 Dec; 367(3):551-563. PubMed ID: 30275151
[TBL] [Abstract][Full Text] [Related]
4. Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative.
Silva NR; Gomes FV; Fonseca MD; Mechoulam R; Breuer A; Cunha TM; Guimarães FS
Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):369-377. PubMed ID: 28720466
[TBL] [Abstract][Full Text] [Related]
5. Cannabidiol disrupts the consolidation of specific and generalized fear memories via dorsal hippocampus CB
Stern CAJ; da Silva TR; Raymundi AM; de Souza CP; Hiroaki-Sato VA; Kato L; Guimarães FS; Andreatini R; Takahashi RN; Bertoglio LJ
Neuropharmacology; 2017 Oct; 125():220-230. PubMed ID: 28754373
[TBL] [Abstract][Full Text] [Related]
6. A multi-target approach for pain treatment: dual inhibition of fatty acid amide hydrolase and TRPV1 in a rat model of osteoarthritis.
Malek N; Mrugala M; Makuch W; Kolosowska N; Przewlocka B; Binkowski M; Czaja M; Morera E; Di Marzo V; Starowicz K
Pain; 2015 May; 156(5):890-903. PubMed ID: 25719612
[TBL] [Abstract][Full Text] [Related]
7. Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.
Nasirinezhad F; Jergova S; Pearson JP; Sagen J
Neuropharmacology; 2015 Aug; 95():100-9. PubMed ID: 25486617
[TBL] [Abstract][Full Text] [Related]
8. The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
Russo R; Loverme J; La Rana G; Compton TR; Parrott J; Duranti A; Tontini A; Mor M; Tarzia G; Calignano A; Piomelli D
J Pharmacol Exp Ther; 2007 Jul; 322(1):236-42. PubMed ID: 17412883
[TBL] [Abstract][Full Text] [Related]
9. Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation.
Costa B; Giagnoni G; Franke C; Trovato AE; Colleoni M
Br J Pharmacol; 2004 Sep; 143(2):247-50. PubMed ID: 15313881
[TBL] [Abstract][Full Text] [Related]
10. Piperazinyl carbamate fatty acid amide hydrolase inhibitors and transient receptor potential channel modulators as "dual-target" analgesics.
Maione S; Costa B; Piscitelli F; Morera E; De Chiaro M; Comelli F; Boccella S; Guida F; Verde R; Ortar G; Di Marzo V
Pharmacol Res; 2013 Oct; 76():98-105. PubMed ID: 23911581
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of FAAH reduces nitroglycerin-induced migraine-like pain and trigeminal neuronal hyperactivity in mice.
Nozaki C; Markert A; Zimmer A
Eur Neuropsychopharmacol; 2015 Aug; 25(8):1388-96. PubMed ID: 25910421
[TBL] [Abstract][Full Text] [Related]
12. Actions of the dual FAAH/MAGL inhibitor JZL195 in a murine inflammatory pain model.
Anderson WB; Gould MJ; Torres RD; Mitchell VA; Vaughan CW
Neuropharmacology; 2014 Jun; 81():224-30. PubMed ID: 24384256
[TBL] [Abstract][Full Text] [Related]
13. Cannabidiol has therapeutic potential for myofascial pain in female and male parkinsonian rats.
Vivanco-Estela AN; Dos-Santos-Pereira M; Guimaraes FS; Del-Bel E; Nascimento GCD
Neuropharmacology; 2021 Sep; 196():108700. PubMed ID: 34246682
[TBL] [Abstract][Full Text] [Related]
14. Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels.
Micale V; Cristino L; Tamburella A; Petrosino S; Leggio GM; Drago F; Di Marzo V
Neuropsychopharmacology; 2009 Feb; 34(3):593-606. PubMed ID: 18580871
[TBL] [Abstract][Full Text] [Related]
15. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
[TBL] [Abstract][Full Text] [Related]
16. Non-cannabinoid CB1, non-cannabinoid CB2 antinociceptive effects of several novel compounds in the PPQ stretch test in mice.
Haller VL; Cichewicz DL; Welch SP
Eur J Pharmacol; 2006 Sep; 546(1-3):60-8. PubMed ID: 16919265
[TBL] [Abstract][Full Text] [Related]
17. Fatty acid amide hydrolase blockade attenuates the development of collagen-induced arthritis and related thermal hyperalgesia in mice.
Kinsey SG; Naidu PS; Cravatt BF; Dudley DT; Lichtman AH
Pharmacol Biochem Behav; 2011 Oct; 99(4):718-25. PubMed ID: 21740924
[TBL] [Abstract][Full Text] [Related]
18. The dual fatty acid amide hydrolase/TRPV1 blocker, N-arachidonoyl-serotonin, relieves carrageenan-induced inflammation and hyperalgesia in mice.
Costa B; Bettoni I; Petrosino S; Comelli F; Giagnoni G; Di Marzo V
Pharmacol Res; 2010 Jun; 61(6):537-46. PubMed ID: 20138997
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors.
Járai Z; Wagner JA; Varga K; Lake KD; Compton DR; Martin BR; Zimmer AM; Bonner TI; Buckley NE; Mezey E; Razdan RK; Zimmer A; Kunos G
Proc Natl Acad Sci U S A; 1999 Nov; 96(24):14136-41. PubMed ID: 10570211
[TBL] [Abstract][Full Text] [Related]
20. The anxiolytic effects of cannabidiol in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling.
Fogaça MV; Campos AC; Coelho LD; Duman RS; Guimarães FS
Neuropharmacology; 2018 Jun; 135():22-33. PubMed ID: 29510186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
